Literature DB >> 17180618

Risk of adverse behavioral effects with pediatric use of antidepressants.

Wayne K Goodman1, Tanya K Murphy, Eric A Storch.   

Abstract

OBJECTIVES: This article reviews evidence that led the Food and Drug Administration to issue a "black box" warning about the risk of "suicidality" (suicidal thoughts and behavior) in children and adolescents during treatment with antidepressants.
RESULTS: Re-analysis of data from randomized clinical trials of antidepressants in the pediatric population revealed a significantly greater overall (all drugs across all indications) risk ratio for drug 1.95 (95% Cl, 1.28-2.98) compared to placebo in this sample of approximately 4,000 subjects. DISCUSSION: The essential message of the "black box" is to remind prescribers and consumers about the importance of monitoring closely for adverse behavioral changes during the initiation of (or changes in) antidepressant therapy. Possible mechanisms that might account for this phenomenon, particularly the so-called activation syndrome, are discussed.
CONCLUSION: Empirical studies are needed to identify the precursors of suicidality and to predict which individuals are most susceptible to adverse behavioral side effects of antidepressants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17180618     DOI: 10.1007/s00213-006-0642-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  61 in total

1.  The development of selective inhibitory control across the life span.

Authors:  Anne-Claude Bedard; Shana Nichols; José A Barbosa; Russell Schachar; Gordon D Logan; Rosemary Tannock
Journal:  Dev Neuropsychol       Date:  2002       Impact factor: 2.253

Review 2.  Managing antipsychotic-induced acute and chronic akathisia.

Authors:  C H Miller; W W Fleischhacker
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

3.  Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult.

Authors:  Cornelius Gross; Xiaoxi Zhuang; Kimberly Stark; Sylvie Ramboz; Ronald Oosting; Lynn Kirby; Luca Santarelli; Sheryl Beck; René Hen
Journal:  Nature       Date:  2002-03-28       Impact factor: 49.962

4.  Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database.

Authors:  A Khan; S R Khan; R M Leventhal; W A Brown
Journal:  Int J Neuropsychopharmacol       Date:  2001-06       Impact factor: 5.176

Review 5.  Diagnosis and treatment of bipolar disorder in children and adolescents.

Authors:  Karen Dineen Wagner
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

Review 6.  The impact of bipolar depression.

Authors:  Robert M Post
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

7.  Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial.

Authors:  Gregory K Brown; Thomas Ten Have; Gregg R Henriques; Sharon X Xie; Judd E Hollander; Aaron T Beck
Journal:  JAMA       Date:  2005-08-03       Impact factor: 56.272

8.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

Review 9.  Some aspects of genetic polymorphism in the biotransformation of antidepressants.

Authors:  Kim Brøsen
Journal:  Therapie       Date:  2004 Jan-Feb       Impact factor: 2.070

10.  Antidepressants and the risk of suicidal behaviors.

Authors:  Hershel Jick; James A Kaye; Susan S Jick
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

View more
  17 in total

1.  The role of co-occurring disruptive behavior in the clinical presentation of children and adolescents with anxiety in the context of autism spectrum disorders.

Authors:  Eric A Storch; Elysse B Arnold; Anna M Jones; Chelsea M Ale; Jeffrey J Wood; Jill Ehrenreich-May; Adam B Lewin; P Jane Mutch; Tanya K Murphy
Journal:  Child Psychiatry Hum Dev       Date:  2012-10

2.  Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile.

Authors:  Jeannette M Reid; Eric A Storch; Tanya K Murphy; Danielle Bodzin; P Jane Mutch; Heather Lehmkuhl; Michael Aman; Wayne K Goodman
Journal:  Child Youth Care Forum       Date:  2010-02-04

Review 3.  Pharmacotherapy for Pediatric Generalized Anxiety Disorder: A Systematic Evaluation of Efficacy, Safety and Tolerability.

Authors:  Eric T Dobson; Jeffrey R Strawn
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

4.  Intensive Family-Based Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder: Applications for Treatment of Medication Partial- or Nonresponders.

Authors:  Wendi E Marien; Eric A Storch; Gary R Geffken; Tanya K Murphy
Journal:  Cogn Behav Pract       Date:  2009-08

5.  Paroxetine-induced increase in activity of locus coeruleus neurons in adolescent rats: implication of a countertherapeutic effect of an antidepressant.

Authors:  Charles Hutchison Keesor West; James Carl Ritchie; Jay Michael Weiss
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

6.  Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention.

Authors:  Joseph F McGuire; Adam B Lewin; Daniel A Geller; Ashley Brown; Kesley Ramsey; Jane Mutch; Andrew Mittelman; Jamie Micco; Cary Jordan; Sabine Wilhelm; Tanya K Murphy; Brent J Small; Eric A Storch
Journal:  Neuropsychiatry (London)       Date:  2012-08

7.  Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD.

Authors:  Regina Bussing; Tanya K Murphy; Eric A Storch; Joseph P H McNamara; Adam M Reid; Cynthia W Garvan; Wayne K Goodman
Journal:  Psychiatry Res       Date:  2012-09-29       Impact factor: 3.222

Review 8.  Common Factors in Pediatric Psychiatry: A Review of Essential and Adjunctive Mechanisms of Treatment Outcome.

Authors:  Alessandro S De Nadai; Marc S Karver; Tanya K Murphy; Mark A Cavitt; Jeffrey L Alvaro; Michael Bengtson; Saundra Stock; Andrew C Rakhshani; Eric A Storch
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-04-29       Impact factor: 2.576

Review 9.  Animal models of suicide-trait-related behaviors.

Authors:  Oz Malkesman; Daniel S Pine; Tyson Tragon; Daniel R Austin; Ioline D Henter; Guang Chen; Husseini K Manji
Journal:  Trends Pharmacol Sci       Date:  2009-03-05       Impact factor: 14.819

10.  The Moderating Role of Child Maltreatment in Treatment Efficacy for Adolescent Depression.

Authors:  Sheree L Toth; Elizabeth D Handley; Jody Todd Manly; Robin Sturm; Tangeria R Adams; Elizabeth M Demeusy; Dante Cicchetti
Journal:  J Abnorm Child Psychol       Date:  2020-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.